Methicillin-resistant Staphylococcus aureus in acute otitis externa

Maria J. Duarte
Harvard Medical School

Let us know how access to this document benefits you.
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs

Part of the Bacterial Infections and Mycoses Commons, Otolaryngology Commons, and the Otorhinolaryngologic Diseases Commons

Repository Citation
Duarte MJ, Kozin ED, Bispo PJ, Mitchell AH, Gilmore MS, Remenschneider AK. (2017). Methicillin-resistant Staphylococcus aureus in acute otitis externa. Open Access Publications by UMMS Authors. https://doi.org/10.1016/j.wjorl.2017.09.003. Retrieved from https://escholarship.umassmed.edu/oapubs/3695

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License. This material is brought to you by eScholarship@UMassChan. It has been accepted for inclusion in Open Access Publications by UMMS Authors by an authorized administrator of eScholarship@UMassChan. For more information, please contact Lisa.Palmer@umassmed.edu.
Research Paper

Methicillin-resistant Staphylococcus aureus in acute otitis externa☆

Maria J. Duarte a,b,*, Elliott D. Kozin a,b, Paulo J.M. Bispo c,d,e, Andreas H. Mitchell a, Michael S. Gilmore c,d,e, Aaron K. Remenschneider a,b,f

a Department of Otology and Laryngology, Harvard Medical School, Boston, MA, USA
b Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Boston, MA, USA
c Department of Ophthalmology, Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston, MA, USA
d Department of Microbiology, Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston, MA, USA
e Department of Immunobiology, Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston, MA, USA
f University of Massachusetts Medical School, Worcester, MA, USA

Received 10 May 2017; received in revised form 12 September 2017; accepted 18 September 2017
Available online 23 November 2017

KEYWORDS
Acute otitis externa; Staphylococcus aureus; Methicillin-resistant Staphylococcus aureus, MRSA

Abstract  Objective: Otologic methicillin-resistant Staphylococcus aureus (MRSA) infection has historically been rare, but given the rise in community-acquired MRSA carriage and infection at other body sites, prevalence rates may be changing. The goal of this study was to determine the prevalence of MRSA in recent otologic cultures from patients with acute otitis externa (AOE).

Study design: Retrospective review of an institutional microbiologic database.

Methods: A retrospective analysis was performed on serial culture isolates taken from the ear at a quaternary care hospital from January 2014 to April 2016. The causative pathogen and antibiotic sensitivity was determined by culture isolation and end point mean inhibitory concentration (MIC) testing. Medical records were reviewed to document patient characteristics, chronicity of infection, symptomatology, and previous treatments.

* Presented at: 2017 Triological Society Combined Sections Meeting, New Orleans, LA.
* Corresponding author. Massachusetts Eye and Ear Infirmary, 243 Charles Street, Boston, MA 02114, USA.
E-mail address: maria_duarte@meei.harvard.edu (M.J. Duarte).
Peer review under responsibility of Chinese Medical Association.

https://doi.org/10.1016/j.wjorl.2017.09.003
2095-8811/Copyright © 2017 Chinese Medical Association. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Results: Over the study period, 173 patients were diagnosed with AOE and underwent ototopical antibiotic treatments. Of these, 53 (30.6%) were MRSA positive. Compared to patients with MSSA, patients with MRSA were significantly more likely to have had prior ototopical antibiotic exposure (37% vs 73%, P = 0.019). Clinicians should consider ear cultures to identify MRSA AOE. 

Level of Evidence: IV. 

Introduction

Acute otitis externa (AOE) is a common otologic condition, affecting 1 of every 10 individuals. Defined as an infection of the skin and soft tissue of the external auditory canal, AOE can be caused by a variety of bacteria or fungi. While most symptoms of AOE are mild, complications of AOE may be serious, including necrotizing infection, facial nerve paralysis, osteomyelitis, and rarely death. 

The implicated pathogens in acute bacterial otitis externa vary geographically, but most commonly involve Pseudomonas and Staphylococcus aureus. Pseudomonas species are estimated to be responsible for 20%–71.3% of cases. S. aureus is thought to be the second most common pathogen in acute bacterial otitis externa, with case series identifying S. aureus in up to 40% of cases. Studies from Pakistan, Korea and New Zealand found rates of S. aureus AOE above 30%, while the most recent study in the U.S. reported rates of 7.8%.

Current guidelines for treatment of otitis externa focus on Pseudomonas spp. and S. aureus because of their high incidence in AOE. Generally, empiric management with topical antibiotics targeting non-resistant strains of these bacteria is recommended. A 2014 update of the clinical practice guidelines (American Academy of Otolaryngology-Head and Neck Surgery [AAO-HNS]) identifies topical fluoroquinolones, aminoglycosides, and/or polymyxin B for empiric treatment. While most systematic reviews have found no significant difference in treatment outcomes with antiseptic or different types of antibiotic drops treating AOE, two meta analyses by Rosenfeld et al and Mösgen et al suggest that quinolone drops resulted in higher rates of bacteriologic and clinical cure — defined as the absence of pathogen on follow up and resolution of clinical symptoms. At present, empiric treatment with ototopical antibiotic drops is recommended, unless there is extension of infection outside the ear canal, or the patient has concerning host factors such as immunocompromise or diabetes. In such cases, the inclusion of systemic antibiotics is appropriate.

While sensitive S. aureus may be treated similarly to other gram positive bacteria, methicillin-resistant S. aureus (MRSA) otitis externa, represents a greater therapeutic challenge. Since their initial detection in the 1960’s, MRSA infections in the U.S. have been typically associated mainly with hospitalized patients. MRSA represents a significant healthcare burden worldwide, as patients with MRSA have more difficult-to-treat infections, associated with longer hospital stays, and a much higher cost-of-care. Another risk factor for MRSA is recent exposure to antibiotics, especially quinolones.

While MRSA remained mainly nosocomial in nature through the 1980’s, community-acquired MRSA (CA-MRSA) emerged in the 1990’s and has become increasingly common in soft tissue and otolaryngologic infections since. In 2002, Hwang et al reported >8.5% increase in CA-MRSA incidence in otologic infections in Taiwan. Similarly, in 2007 a group from Hawaii noted a rapid increase in CA-MRSA head and neck infections from 21% to 64% over a five-year period. Despite the rise of MRSA soft tissue infections, few studies have examined contemporary clinical features and incidence patterns of MRSA in AOE. In the UK, an English 2007 study and an Irish 2001 study have reported rates of 0.7% and 6%, respectively. The most recently published work on uncomplicated AOE, a 2012 study from Singapore, reported a MRSA AOE rate of 4.2%. Studies in South Africa, Pakistan and Korea found no MRSA in AOE cultures, consistent with the low levels of MRSA colonization of their populations. 

The aim of the current study was to determine contemporary incidence rates, resistance patterns and clinical features of MRSA AOE diagnosed and treated at a quaternary care center in the United States.

Materials and methods

A retrospective chart review was performed on all patients at a quaternary care center with an available otologic culture between January 2014 and April 2016. Inclusion criteria included patients presenting with acute otologic symptoms who were clinically diagnosed with AOE, and who underwent an ear culture. Exclusion criteria included patients presenting with otitis media, chronic otitis externa, primarily non-otologic symptoms, hospitalized patients, and post-operative patients. While all patients presented from the community, some had recent outpatient exposure to antibiotic agents, and a thorough review of their chart
included topical antibiotics used in the affected ear over the preceding 6 months. Other information gathered from the patient chart included demographics, comorbidities, symptomatology, physical exam findings, and otologic outcomes. Comorbidities evaluated included otorrhea disease (i.e., chronic otitis, existing hearing aid or other prosthesis) and systemic disease (with special attention given to diabetes, immunocompromise, and malignancy).

Bacterial culture findings and antibiotic resistance patterns on included patients were reviewed. Swabs were taken from the site of infection and cultured on various agars, following standard institutional microbiological analysis protocols. Bacterial identification and antibiotic susceptibility testing were performed using the MicroScan WalkAway 40 Plus System (Beckman Coulter).

Statistical analysis of the collected data was performed using Stata statistical software (StataCorp, 2015). Pearson’s \( \chi^2 \) test and unpaired t-tests were performed to determine significant associations in the microbial patterns and patient data. A \( \text{P} \) value of <0.05 was considered statistically significant. This study was approved by the Human Subjects Committee of our Institutional Review Board (Protocol #914379).

Results

Patient demographics

From 2014 to 2016, 179 patients had a clinical diagnosis of AOE and available culture data supporting the diagnosis of a bacterial infection. Six patients with concomitant chronic otitis media were excluded from the study. Of the remaining 173 patients, 45.7% (79/173) were male. The mean age was 34.2 \( \pm \) 23.8. Adult patients (defined as patients \( \geq \)18 years old) comprised 66% of the study population.

Bacterial isolates in otitis externa

Of the 173 patients, 73 (42.2%) yielded *Pseudomonas aeruginosa* as the primary pathogen identified. *S. aureus* was the second most commonly isolated pathogen (53/173, 30.6%). Of the 53 *S. aureus* isolates, 38 (71.7%) were methicillin-sensitive *S. aureus* (MSSA) and 15 (28.3%) were methicillin-resistant *S. aureus* (MRSA). Thus, 22.0% (38/173) of all AOE patients analyzed were infected with MSSA, and 8.7% (15/173) with MRSA. The next most common species isolated from AOE cases was *Enterococcus faecalis* (5.2%). *Escherichia coli*, *Stenotrophomonas maltophilia*, and *Streptococcus pneumoniae* each were isolated from 2.3% of patients (Table 1).

Comparison of demographics and symptomatology of MSSA and *P. aeruginosa* AOE versus MRSA AOE

The average age of the 38 patients with MSSA was 29.0 \( \pm \) 19.4 (range 5–74), and 13/38 (34%) were pediatric patients. The average age for the 73 patients with *P. aeruginosa* was 31.2 \( \pm \) 22.7 (range 1–90), and 28/73 (38%) were pediatric patients. In contrast, the average age of patients with MRSA was 47.7 \( \pm \) 17.9 (range 13–68), and included only one pediatric patient. Of patients with MSSA, 36% were male (Table 2), whereas there was a slight male predominance (54%) among MRSA AOE cases.

The average number of comorbidities (defined as systemic chronic conditions at the time of culture) for AOE associated with MSSA was 4 (range 0–12), which was significantly higher than for MRSA patients at 0.8 (range 0–3), \( \text{P} < 0.01 \) and *P. aeruginosa* patients at 1 (range 0–2), \( Z = 4.7, \text{P} < 0.01 \). Of 15 AOE patients with MRSA, one was diabetic and two were immunocompromised. No patient with MSSA had either diabetes or was immunocompromised.

All three groups of AOE patients presented with similar symptoms (Table 3). The most common symptoms were otorrrhea, otalgia, swelling, and hearing loss/blocked ear. Swelling was more common in MRSA associated cases (33.3%) compared MSSA cases (5.3%, \( Z = 4.03, \text{P} = 0.01 \)), and *P. aeruginosa* cases (19.2%, \( Z = 2.3, \text{P} = 0.03 \)). Patients with *Pseudomonas* were more likely to present with otalgia than MRSA patients (83.6% vs 60.0%, \( Z = 2.7, \text{P} = 0.01 \)). Data on time to resolution of symptoms was available for only a subset of patients who had several follow up visits. Mean time to resolution was calculated from the point in the clinical history at which the patient reported no longer being symptomatic. Resolution of symptoms appeared to take
longer in MRSA infected patients (21.5 days) than in patients with P. aeruginosa (15 days) and patients with MSSA (11.2 days). The difference in resolution of symptoms was statistically significant for P. aeruginosa versus MRSA patients ($P < 0.04$). Due to the smaller numbers of MSSA patients included, the difference between MRSA and MSSA patients did not achieve significance ($P > 0.11$).

### Antibiotic sensitivities

MRSA isolates were significantly more likely ($P < 0.05$) than MSSA isolates to be resistant to multiple antibiotics, including erythromycin and levofloxacin. Both groups exhibited high proportions of resistance to amikacin (Table 4).

A sub-analysis of AOE patients with prior exposure to otic antibiotic drops (ciprofloxacin, ofloxacin, tobramycin, neomycin, gentamicin) was performed. Of 53 total patients infected with S. aureus, 25 (47.1%) had a prior history of antibiotic otic drops within the past 6 months. Of those using drops, 11 were infected with MRSA (73.3% of MRSA isolates) and 14 were infected with MSSA (36.8% of MSSA isolates, Table 2). The most common exposure was to quinolone drops, in 9 out of 11 previously exposed patients with MRSA isolates. This was significantly different from patients with MSSA, in which 8 out 14 previously exposed patients had been exposed to quinolone drops ($P = 0.019$).

### Tables

#### Table 2
Demographics presentation, and previous exposure to antibiotic drops of S. aureus acute otitis externa infections. Nine out of 11 patients with MRSA exposed to otic drops were exposed to quinolone drops.**Significantly different from MRSA.

| Group          | Average age (y) | Sex      | Average number of comorbidities | Average time to resolution of symptoms (days) | Previous exposure to otic drops |
|----------------|----------------|----------|--------------------------------|-----------------------------------------------|--------------------------------|
| MRSA           | 46.7 (13–68; 1 pedi patient) | 54% M; 46% F | 4 (0–12)                         | 21.5 (3–42; data available for n = 6)     | 11 (73%)                        |
| MSSA           | 29.0 (5–74; 13 pedi patients, $P < 0.01$)** | 36% M; 64% F | 1.7 (0–6, $P < 0.01$)** | 11.2 (1–42)                         | 14 (37%, $P = 0.019$)**         |
| P. aeruginosa  | 31.2 (1–90; 28 pedi patients, $P = 0.014$)** | 46.6% M; 53.4% F | 1 (0–2, $P < 0.01$)** | 15 (2–56, $P = 0.04$)**               | 35 (48%)                        |

#### Table 3
Symptoms of S. aureus acute otitis externa infections. *$P < 0.05$; **Significantly different from MRSA.

| Group          | n   | Otorrhea cases (%) | Otalgia cases (%) | Swelling* cases (%) | Hearing loss cases (%) |
|----------------|-----|--------------------|-------------------|--------------------|------------------------|
| MRSA           | 15  | 9 (60.0)           | 9 (60.0)          | 5 (33.3)           | 4 (26.7)               |
| MSSA           | 38  | 23 (60.5)          | 19 (50.0)         | 2 (5.3)**($P < 0.01$) | 5 (13.2)               |
| P. aeruginosa  | 73  | 47 (64.3)          | 61 (83.6%)**($P = 0.04$) | 14 (19.2)         | 23 (31.5)              |

#### Table 4
Proportion of S. aureus isolates resistant to listed antibiotics. NA: Not applicable. *$P < 0.05$.

| Antibiotic                  | MRSA Number (%) of specimens showing resistance to antibiotic | MSSA Number (%) of specimens showing resistance to antibiotic | $P$ value |
|-----------------------------|--------------------------------------------------------------|-------------------------------------------------------------|-----------|
| Amikacin                    | 13 (100)                                                     | 1 (100)                                                     | NS        |
| Amoxicillin/Clavulanate     | NA                                                           | 22 (100)                                                    | NA        |
| Ampicillin                  | NA                                                           | 5 (71.4)                                                    | NA        |
| Clindamycin                 | 0 (0)                                                        | 7 (18.4)                                                    | 0.51      |
| Daptomycin                  | 0 (0)                                                        | 0 (0)                                                       | NS        |
| Erythromycin*               | 12 (80)                                                      | 9 (25.7)                                                    | $<0.001$ |
| Gentamicin                  | 1 (6.67)                                                     | 0 (0)                                                       | 0.11      |
| Levofloxacin*               | 5 (33.3)                                                     | 2 (5.26)                                                    | 0.007     |
| Linezolid                   | 0 (0)                                                        | 0 (0)                                                       | NA        |
| Penicillin*                 | NA                                                           | 28 (73.68)                                                  | NA        |
| Tetracycline                | 1 (6.67)                                                     | 2 (5.4)                                                     | 0.51      |
| Trimethoprim/sulfamethoxazole | 1 (6.67)                                                  | 1 (2.7)                                                     | 0.86      |
| Vancomycin                  | 0 (0)                                                        | 0 (0)                                                       | NA        |
Discussion

In the current study, we found *S. aureus* as the likely pathogen of AOE in 30.6% of cases, which is higher than previously reported in the U.S., which found a rate of 7.8%. This difference could be reflective of changing population demographics and/or changes in the nature of strains of *S. aureus* occurring in the community. Local modifications in the external ear microbial population may also result from the selective pressure imposed by empirical antibiotic treatment. As the likely causative agent of 1 in 3 AOE cases, *S. aureus* should be factored into antimicrobial coverage decisions on initiation of empiric treatment.

Among patients with *S. aureus* otitis externa, we identified MRSA in 8.7% of cases — over three times the last reported U.S. rate, from 2002 (Table 5). Because the incidence of MRSA in soft tissue infection is reflective of carriage rate in the population, understanding our evolving incidence of MRSA in soft tissue infection is reflective of MRSA carriage and infection over the past 20 years. The increased incidence observed in our study, when compared to the earlier findings of Roland et al was reported over 15 years ago. Our search of the literature yielded only one other U.S. study examining the epidemiology of MRSA otitis: a 2014 study from Pittsburgh Medical Center, which reported an MRSA rate of 15% among malignant otitis externa cases caused by *S. aureus*. These findings may indicate that MRSA AOE, when not identified and treated early, may more frequently result in advanced disease and complications.

While little is known about MRSA in AOE, increasing rates of MRSA in soft tissue infections and in otolaryngology are well-documented. The increased incidence observed in our study, when compared to the earlier findings of Roland et al appear to be consistent with the global trend of increasing prevalence of community-acquired MRSA carriage and infection over the past 20 years.

In general, we found that MRSA AOE presented with a spectrum of symptoms similar to infections caused by MSSA, but was more likely to be associated with significant ear canal swelling. Rapid onset, severe swelling, tenderness and erythema have been observed before in MRSA head and neck infections, and, when encountered, should raise the index of suspicion of MRSA otitis for the clinician. Patients with MRSA tended to experience a longer time to resolution of symptoms. MRSA AOE tended to be associated with diabetes, immunocompromise and comorbidities to a greater degree than MSSA.

In fact, the only case of malignant otitis externa among this cohort was a patient with MRSA AOE. Because of the potential for extended-duration, more severe infection, care providers should consider MRSA AOE when a patient presents and fail to improve quickly with empiric treatment.

We also found that patients with MRSA had a higher exposure to previous ototopical drops than did patients with MSSA AOE. In fact, 73% of patients with MRSA had been exposed to otic drops in the past 6 months, and of these, most had been exposed to quinolone drops. Exposure to prior ototopical drops may select for resistant organisms, allowing them to become the primary pathogen during an episode of AOE. The ophthalmology literature studying the use of quinolone drops on corneal ulcers has demonstrated a significant increase in resistant organisms after the use of fluoroquinolone drops. Similarly, a higher level of nasal MRSA colonization has been found in patients exposed to fluoroquinolones. Other work by Venezia et al has shown a mechanistic link between quinolone usage and selection for oxacillin-resistant organisms, and concluded that exposure to fluoroquinolones greatly increases the likelihood of developing MRSA, even in as short a period as 8 h after exposure. A 2004 meta-analysis of otologic infections concluded that empiric antibiotic drops were unlikely to be associated with the development of resistant organisms. However, this study was limited by very small sample size (2 patients with OE), and is now over 10 years old. It is possible that the microbiologic landscape has changed significantly in intervening years. Larger, contemporary studies in OE should be performed to better understand the relationship between empiric antibiotic therapy and the rise in MRSA infections.

Notwithstanding the effects of quinolones in selecting for MRSA, the fact that in our study almost 1 in 10 patients with AOE had MRSA highlights the importance of adequate treatment and close follow up of the disease. MRSA is a known cause of chronic otitis media (COM) and chronic otorrhea, and clinical algorithms focused on topical vancomycin therapy have been developed to guide clinicians in treating those cases. No such algorithm exists for MRSA in otitis externa. However, clinical guidelines on antibiotic use in otolaryngology currently recommend using vancomycin drops in ears affected by MRSA, and practitioners should follow this for AOE. At our institution, once external auditory infection with MRSA is confirmed via culture, vancomycin drops (25 mg/ml) twice daily or tobramycin drops (13.6 mg/ml) three times daily for ten days are

| Year published | Location | Type of institution | Years of data collection | MRSA AOE | MSSA AOE |
|----------------|----------|--------------------|--------------------------|----------|----------|
| Duarte et al | 2017 United States | Tertiary | 2014–2016 | 8.7% (n = 15) | 22.0% (n = 38) |
| Roland et al | 2002 United States | Various | 1998–2000 | 2.70% (n = 6) | 7.80% (n = 215) |
| Roland et al | 2007 United Kingdom | Tertiary | 2006 | 0.70% (n = 1) | 9% (n = 13) |
| Walshe et al | 2001 Ireland | Primary | 2000 | 6% (n = 15) | 23.80% (n = 57) |
| Meyer et al | 2013 South Africa | Tertiary | 2005–2009 | 0 | 24% (n = 5) |
| Cheong et al | 2012 Singapore | Tertiary | 2010–2011 | 4.20% (n = 2) | 21% (n = 16) |
| Arshad et al | 2004 Pakistan | Primary | 2002–2003 | 0 | 38% (n = 41) |
| Kim et al | 2016 Korea | Tertiary | 1995, 2000, 2004, 2013 | 0 | 36% (n = 63) |
| Jayakar et al | 2014 New Zealand | Various | 2007–2011 | 0 | 31.90% (n = 46) |
prescribed, and the patient is followed closely with serial exams. Based on our institution’s guidelines and the data available for MRSA COM, we propose a modified clinical algorithm for AOE that includes consideration of MRSA infections and the implementation of otologic cultures at the point where the current guidelines recommend re-assessing patients who are not improving with standard antibiotic therapy (Fig. 1, modified from the 2014 AAO-HNS clinical practice guidelines). Given the increasing prevalence of MRSA in AOE in this study and in otolaryngologic infections worldwide, robust trials elucidating the optimal topical antibiotic regimen (vancomycin or otherwise) may be warranted.

This study is limited to only one geographic region in the U.S. (New England), and to patients presenting to our institution who had otologic cultures. While primary cultures are routinely taken on patients presenting to our institution, this practice is not uniform and cultures were not obtained on all patients presenting with AOE. Additionally, many patients with AOE are diagnosed and treated

---

**Fig. 1** Clinical treatment algorithm for otitis externa. **In Black:** Current treatment algorithm for treating acute otitis externa, from the 2014 Clinical Practice Guideline on Acute Otitis Externa, published by the American Academy of Otolaryngology and Head and Neck Surgery. **In Blue:** Proposed modified AAO-HNS algorithm: if there is no clinical improvement with empiric treatment after 72 h, reassess patient and consider MRSA as a potential source of infection.
clinically by primary care physicians and do not reach our institution for culture, follow up and inclusion in this study. While we focused our analysis on bacterial AOE, and not OE of a fungal etiology, these patients represented a small minority of patients with AOE (Table 1). The review was retrospective, thus some data was incomplete and may be subject to selection bias. In addition, this study was performed in a quaternary care center, which serves as a referral site for community physicians. It is possible that patients were exposed to unknown antibiotic treatment before presentation, and that follow up with community physicians inadequately captured the patient’s entire course of disease.

### Conclusion

Contemporary ear culture isolates at quaternary care center show higher rates of MRSA compared to historical reports in the literature. Clinicians should consider ear cultures to identify MRSA AOE.

### Conflicts of interest

None.

### Disclosures

None.

### External sources of funding

None.

### References

1. Centers for Disease Control and Prevention (CDC). Estimated burden of acute otitis externa—United States, 2003-2007. MMWR Morb Mortal Wkly Rep. 2011;60:605–609.
2. Rosenfeld RM, Schwartz SR, Cannon CR, et al. Clinical practice guideline: acute otitis externa. Otolaryngol Head Neck Surg. 2014;150:51–524.
3. Roland PS, Stroman DW. Microbiology of acute otitis externa. Laryngoscope. 2002;112:1166–1177.
4. Hobson CE, May JD, Byers KE, Raz Y, Hirsch BE, McCall AA. Malignant otitis externa: evolving pathogens and implications for diagnosis and treatment. Otolaryngol Head Neck Surg. 2014;151:112–116.
5. Kalantar E, Mosaei M, Ekrami A, Pedram M. Isolation and antimicrobial susceptibility of bacteria from external ear canal of cancer patients at Shafa Cancer Hospital-Ahwaz. J Cancer Res Ther. 2006;2(1):17–19.
6. Ninkovic G, Dullo V, Saunders NC. Microbiology of otitis externa in the secondary care in United Kingdom and antimicrobial sensitivity. Auris Nasus Larynx. 2008;35(4):480–484.
7. Walsh P, Rowley H, Timon C. A worrying development in the microbiology of otitis externa. Clin Otolaryngol Allied Sci. 2001;26:218–220.
8. Meyer E, Whitelaw A, Edkins O, Fagan JJ. Chronic otorrhoea: spectrum of microorganisms and antibiotic sensitivity in a South African cohort. S Afr Med J. 2013;103:471–473.
9. Loh S, Loh WS. Malignant otitis externa: an Asian perspective on treatment outcomes and prognostic factors. Otolaryngol Head Neck Surg. 2013;148:991–996.
10. Arshad M, Khan NU, Ali N, Afriadi NM. Sensitivity and spectrum of bacterial isolates in infectious otitis externa. J Coll Physicians Surg Pak. 2004;14(3):146–149.
11. Kim H, Cho OS, Jang JH, Park HY, Chung YH. Chronological changes in microbial profiles in external and middle ear diseases: a 20-year study in Korea. Eur Arch Otorhinolaryngol. 2017;274(3):1375–1381.
12. Jayakar R, Sanders J, Jones E. A study of acute otitis externa at Wellington Hospital. 2007-2011. Australas Med J. 2014;7(10):392–399.
13. Cheong CS, Tan LM, Ngo RY. Clinical audit of the microbiology of otorrhoea referred to a tertiary hospital in Singapore. Singapore Med J. 2012;53:244–248.
14. Rosenfeld RM, Singer M, Wasserman JM, Stinnett SS. Systematic review of topical antimicrobial therapy for acute otitis externa. Otolaryngol Head Neck Surg. 2006;134:524–548.
15. Mösges R, Nematian-Samani M, Hellmich M, Shah-Hosseini K. A meta-analysis of the efficacy of quinolone containing otics in comparison to antibiotic-steroid combination drugs in the local treatment of otitis externa. Curr Med Res Opin. 2011;27:2053–2060.
16. Hwarg JH, Tsai HY, Liu TC. Community-acquired meticillin-resistant Staphylococcus aureus infections in discharging ears. Acta Otolaryngol. 2002;122:827–830.
17. Kleven MA, Morrison MA, Nadle J, et al. Invasive meticillin-resistant Staphylococcus aureus infections in the United States. JAMA. 2001;298(15):1763–1771.
18. Baranowski R, Mecinska-Resinska S. Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. Clin Infect Dis. 2000;40(4):562–573.
19. MacDougall C, Powell JP, Johnson CK, Edmond MB, Polk RE. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin Infect Dis. 2005;41:435–440.
20. Venezia RA, Domaracki BE, Evans AM, Preston KE, Graffunder EM. Selection of high-level oxacillin resistance in heteroresistant Staphylococcus aureus by fluoroquinolone exposure. J Antimicrob Chemother. 2001;48:375–381.
21. Bothwell NE, Shvidler J, Cable BB. Acute rise in meticillin-resistant Staphylococcus aureus infections in a coastal community. Otolaryngol Head Neck Surg. 2007;137:942–946.
22. Thirumazhisai SS. Rising methicillin-resistant Staphylococcus aureus infections in ear, nose, and throat diseases. Case Rep Otolaryngol. 2014;2014:253945.
23. Ray KJ, Prajna L, Srinivasan M, et al. Fluoroquinolone treatment and susceptibility of isolates from bacterial keratitis. JAMA Ophthalmol. 2013;131:310–313.
24. Cheng VC, Li IW, Wu AK, et al. Effect of antibiotics on the bacterial load of meticillin-resistant Staphylococcus aureus colonisation in anterior nares. J Hosp Infect. 2008;70:27–34.
25. Weber PC, Roland PS, Hennley M, et al. The development of antibiotic resistant organisms with the use of ototopic medications. Otolaryngol Head Neck Surg. 2004;130:589–594.
26. Jang CH, Song CH, Wang PC. Topical vancomycin for chronic supplicative otitis media with methicillin-resistant Staphylococcus aureus otorrhoea. J Laryngol Otol. 2004;118:645–647.
27. Fairbanks D. Pocket Guide to Antimicrobial Therapy in Otolaryngology – Head and Neck Surgery: American Academy of Otolaryngology-head and Neck Surgery. 13th ed. Alexandria (VA): American Academy of Otolaryngology; 2007.

Edited by Yu-xin Fang